Class Action Notice: Rosen Law Firm reminds investors who purchased Alexandria Real Estate Equities securities between January 27 and October 27, 2025, to apply as lead plaintiffs by January 26, 2026, to participate in the class action and seek compensation.
Potential Compensation Opportunity: Investors can pursue damages in the class action without any upfront costs, highlighting the legal avenue as a crucial remedy for affected investors due to the company's misleading statements.
Lawsuit Background: The lawsuit alleges that Alexandria Real Estate provided overly positive statements regarding its leasing activities and financial growth while concealing the true state of its Long Island City property, resulting in investor losses when the truth emerged, indicating serious issues with the company's disclosure practices.
Law Firm's Advantage: Rosen Law Firm is renowned for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, demonstrating its expertise and resource advantages in handling such cases.
ARE
$47.41+Infinity%1D
Analyst Views on ARE
Wall Street analysts forecast ARE stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ARE is 64.78 USD with a low forecast of 30.00 USD and a high forecast of 104.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
12 Analyst Rating
Wall Street analysts forecast ARE stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ARE is 64.78 USD with a low forecast of 30.00 USD and a high forecast of 104.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Buy
9 Hold
1 Sell
Hold
Current: 46.640
Low
30.00
Averages
64.78
High
104.00
Current: 46.640
Low
30.00
Averages
64.78
High
104.00
Cantor Fitzgerald
Neutral
downgrade
$52 -> $48
2025-12-05
Reason
Cantor Fitzgerald
Price Target
$52 -> $48
2025-12-05
downgrade
Neutral
Reason
Cantor Fitzgerald lowered the firm's price target on Alexandria Real Estate to $48 from $52 and keeps a Neutral rating on the shares. The firm says the company's investor day was titled a "reset" for a company slugging through dam-breaking fundamental headwinds created by extreme levels of oversupply and still tepid demand for lab space. Cantor thinks the company came to the event with appropriate humility and an open book of what lies ahead, which for now isn't pretty.
BofA
Joshua Dennerlein
Neutral
downgrade
$57 -> $50
2025-12-05
Reason
BofA
Joshua Dennerlein
Price Target
$57 -> $50
2025-12-05
downgrade
Neutral
Reason
BofA analyst Joshua Dennerlein lowered the firm's price target on Alexandria Real Estate to $50 from $57 and keeps a Neutral rating on the shares after the company hosted its investor day this week. Management now expects the overall life science market to take 4-5 years to reach equilibrium, versus prior forecasts of 2-3 years, and Alexandria reduced the high end of its FY26 guidance that was initially provided with Q3 earnings, the analyst noted.
Baird
Wesley Golladay
Outperform
to
NULL
downgrade
$73 -> $67
2025-12-04
Reason
Baird
Wesley Golladay
Price Target
$73 -> $67
2025-12-04
downgrade
Outperform
to
NULL
Reason
Baird analyst Wesley Golladay lowered the firm's price target on Alexandria Real Estate to $67 from $73 and keeps an Outperform rating on the shares. The firm updated its model following its Investor Day.
BMO Capital
John Kim
Outperform
to
NULL
downgrade
$67 -> $60
2025-12-04
Reason
BMO Capital
John Kim
Price Target
$67 -> $60
2025-12-04
downgrade
Outperform
to
NULL
Reason
BMO Capital analyst John Kim lowered the firm's price target on Alexandria Real Estate to $60 from $67 and keeps an Outperform rating on the shares. The REIT's investor day was worse-than-expected with a steep 45% dividend cut, FY26 earnings guidance reduced below consensus, and lower-quality earnings with negative 8% same-store net operating income and FY26 capitalized interest guidance of $250M vs. expected $139M, the analyst tells investors in a research note. The market reacted to leverage concerns, though progress on $3.9B of planned dispositions would address this, the firm added.
About ARE
Alexandria Real Estate Equities, Inc. is a life science real estate investment trust. The Company is an owner, operator and developer of collaborative life science, agricultural technology (agtech), and advanced technology mega campuses in AAA innovation cluster locations, including Greater Boston, the San Francisco Bay Area, New York City, San Diego, Seattle, Maryland, and Research Triangle. The Company, through its venture capital platform, provides strategic capital to life science, agrifoodtech, climate innovation, and technology companies. Its tenants include multinational pharmaceutical companies; public and private biotechnology companies; life science product, service and medical device companies; digital health, technology, and agtech companies; academic and medical research institutions; United States government research agencies; non-profit organizations, and venture capital firms. It has a Labspace asset base predominantly concentrated in markets with barriers to entry.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
